GeneDx Holdings Corp. (WGS NASDAQ) stock market data APIs
$85.4116
9.15(10.7%)
as of February 4, 2026
Try our APIs with
free plan!
GeneDx Holdings Corp. Financial Data Overview
Price chart is built with
Anychart
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
Prev. Close
85.4116
Open
94.5617
High
95.5669
Low
82.1627
52 wk Range
55.17-170.87
Market Cap
2 753 M
P/E Ratio
865.7273
Shares Outstanding
28 905 K
Revenue
402 M
EPS
0.49
Beta
2.022
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with GeneDx Holdings Corp. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GeneDx Holdings Corp. data using free add-ons & libraries
Get GeneDx Holdings Corp. Fundamental Data
GeneDx Holdings Corp. Fundamental data includes:
- Net Revenue: 402 M
- EBITDA: 34 663 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-28
- EPS/Forecast: 0.41
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GeneDx Holdings Corp. News
New
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
Key Points Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (A...
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
Key Points Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (A...
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
Key Points Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (A...
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
Key Points Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (A...
Get GeneDx Holdings Corp. fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
